Publications by authors named "R A Kratzke"
Cancer markers are measurable molecules in blood or tissues that are produced by tumor cells or immune cells in response to cancer progression. They play an important role in clinical diagnosis, prognosis, and therapy monitoring. Splicing factor proline- and glutamine-rich (SFPQ) plays an important role in cancer growth and metastasis.
View Article and Find Full Text PDFAs part of our efforts geared towards developing mechanism-based cancer sensitizing agents, we have previously synthesized and characterized novel deazaflavin analogs as potent tyrosyl DNA phosphodiesterase 2 (TDP2) inhibitors for combination treatments with topoisomerase II (TOP2) poisons. Interestingly, the sensitizing effect of a few analogs toward TOP2 poison etoposide (ETP) was associated with a significant increase in intracellular drug accumulation, which could be an alternative mechanism to boost the clinical efficacy of ETP in cancer chemotherapies. Hence, we evaluated more deazaflavin TDP2 inhibitors for their impact on drug retention in cancer cells.
View Article and Find Full Text PDFCancer markers are measurable molecules in the blood or tissue that are produced by tumor cells or immune cells in response to cancer progression. They play an important role in clinical diagnosis, prognosis, and anti-drug monitoring. Although DNA, RNA, and even physical images have been used, proteins continue to be the most common marker.
View Article and Find Full Text PDFArticle Synopsis
- Adjuvant chemotherapy is recommended for stage II and III lung adenocarcinomas, and the study analyzed mutations in different ADC subtypes while evaluating the roles of PD-L1, tumor mutational burden (TMB), and tumor-infiltrating lymphocytes (TILs).
- The research examined clinical and genomic data from 375 patients, finding that the Micropapillary/Solid subtype was most frequently linked to various biomarkers, with PD-L1 negative/high TMB patients showing better survival outcomes than those with PD-L1 negative/low TMB.
- The study concluded that high TMB indicates poor prognosis with adjuvant chemotherapy, suggesting these patients might benefit more from immune checkpoint therapy instead.
New treatments are required to enhance current therapies for lung cancer. Mesothelin is a surface protein overexpressed in non-small cell lung cancer (NSCLC) that shows promise as an immunotherapeutic target in phase I clinical trials. However, the immunosuppressive environment in NSCLC may limit efficacy of these therapies.
View Article and Find Full Text PDF